The Common Drug Review (CDR) is currently welcoming patients to provide input to patient organizations on the manufacturer’s submission for upadacitinib for the treatment of psoriatic arthritis (PsA). For this submission, five Canadian organizations are working together, including, The Canadian Psoriasis Network (CPN), The Canadian Association of Psoriasis Patients (CAPP), the Canadian Arthritis Patient Alliance (CAPA), the Arthritis Society (TAS), and the Canadian Spondylitis Association (CSA).
The survey is available in English and French; it should take you approximately 15 minutes to complete. Please submit your responses by January 11, 2021.
Your responses to this survey will only be shared among key members of our organizations as we work together to provide feedback to the Canadian Drug Review. Your responses will be kept confidential and we will not disclose any identifying information.
For English version of the survey, please follow the link
For French version of the survey, please follow this link